- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 3 Bylaws of Bristol-myers Squibb Company, As Amended As of January 3, 2005
- 4 Five Year Competitive Advance and Revolving Credit Facility Agreement
- 10 Bristol-myers Squibb Company 1983 Stock Option Plan
- 10 Bristol-myers Squibb Company 1987 Deferred Compensation Plan
- 10 Form of Agreement Entered into Between Bristol-myers Squibb Company
- 12 Statement Re Computation of Ratios
- 21 Subsidiaries of the Registrant
- 23 Consent of Pricewaterhousecoopers
- 31 Section 302 Certification Letter
- 31 Section 302 Certification Letter
- 32 Section 906 Certification Letter
- 32 Section 906 Certification Letter
EXHIBIT 32a.
Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as
Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U. S. C. Section 1350, I, Peter R. Dolan, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2004 (the Report), as filed with the Securities and Exchange Commission on March 3, 2005, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.
/s/ PETER R. DOLAN |
Peter R. Dolan Chairman of Board and Chief Executive Officer March 3, 2005 |
This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by Bristol-Myers Squibb Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
A signed original of this written statement required by Section 906 has been provided to Bristol-Myers Squibb Company and will be retained by Bristol-Myers Squibb Company and furnished to the Securities and Exchange Commission or its staff upon request.
E-32-1